News
European Commission approves conditionally Jemperli for use in women with mismatch repair-deficient (dMMR)/microsatellite instability-high recurrent or advanced endometrial cancer. GSK
GlaxoSmithKline has announced the European Commission has granted conditional marketing authorisation for Jemperli(dostarlimab), a programmed death receptor-1 (PD-1)-blocking antibody, for use in women with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer who have progressed on or following prior treatment with a platinum containing regimen.
The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe.
Condition: Mismatch Repair Deficient Endometrial Cancer
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins